Paola Temperani
University of Modena and Reggio Emilia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paola Temperani.
Annals of the New York Academy of Sciences | 1992
Claudio Franceschi; Daniela Monti; Maria Rosaria Scarfì; Olga Zeni; Paola Temperani; Giovanni Emilia; Paolo Sansoni; Maria Brigida Lioi; Leonarda Troiano; Caterina Agnesini; Stefano Salvioli; Andrea Cossarizza
In previous papers we proposed the general hypothesis that aging and longevity are the result of a balance between mechanisms that favor aging and mechanisms that counteract the aging The mechanisms favoring aging and senescence are those that cause damage to macromolecules and other body components. They come from both exogenous and endogenous sources. Ionizing radiation, UV radiation, and xenobiotics, including dietary carcinogens, are the most common exogenous genotoxic compounds with which we cope in everyday life. Body heat, oxygen free radicals, glucose, and other oxidative sugars are representative of the byproducts of a variety of metabolic pathways and represent unavoidable, potentially genotoxic agents3
British Journal of Haematology | 1994
C Messora; L Bensi; Angela Vecchi; Rosina Longo; Francesca Giacobbi; Paola Temperani; Mirco Bevini; Giovanni Emilia; Stefano Sacchi
Summary Polycythaemia vera is a clonal disorder of the haemopoietic stem cell causing a pathologic expansion of the erythroid and sometimes the megakaryocytic and myeloid elements. In order to avoid the possible mutagenic effects of radioactive phosphorus, alkylating agents and hydroxyurea, since 1988 α‐IFN has been used for the treatment of PV and has been shown to induce and maintain haematological remission. We describe a 24‐year‐old PV patient with chromosomal abnormalities who achieved not only a reduction of the proliferation of erythroid elements and reticulin content in the bone marrow, but also a complete cytogenetic remission after IFN treatment.
Cancer Research | 2009
Elisabetta Caprini; Cristina Cristofoletti; Diego Arcelli; Paolo Fadda; Mauro Helmer Citterich; Francesca Sampogna; Armando Magrelli; Federica Censi; Paola Torreri; Marina Frontani; Enrico Scala; Maria Cristina Picchio; Paola Temperani; Alessandro Monopoli; Giuseppe Lombardo; Domenica Taruscio; Maria Grazia Narducci; Giandomenico Russo
In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal aberrations did not show a significant correlation with prognosis; however, when more than three recurrent chromosomal alterations (gain or loss) were considered, a statistical association was observed using Kaplan-Meier survival analysis. Integrating mapping and transcriptional data, we were able to identify a total of 113 deregulated transcripts in aberrant chromosomal regions that included cancer-related genes such as members of the NF-kappaB pathway (BAG4, BTRC, NKIRAS2, PSMD3, and TRAF2) that might explain its constitutive activation in CTCL. Matching this list of genes with those discriminating patients with different survival times, we identify several common candidates that might exert critical roles in SS, such as BUB3 and PIP5K1B. Altogether, our study confirms and maps more precisely the regions of gain and loss and, combined to transcriptional profiles, suggests a novel set of genes of potential interest in SS.
Leukemia & Lymphoma | 1993
Giovanni Emilia; Stefano Sacchi; Paola Temperani; Rosina Longo; Angela Vecchi
We report a 61-year-old man with essential thrombocythemia (ET) whose clinical course was followed for 12 years. The ET evolved into true idiopathic myelofibrosis (IM) 6 years after the initial diagnosis and progressed to myeloid blastic transformation 6 years later. The cytogenetic analysis showed a normal karyotype during the ET phase but subsequent analysis revealed an abnormal karyotype during the IM phase which evolved clonally at blastic crisis with constant involvement of chromosome 13q and chromosome 7. The close monitoring of essential events, using clinical, morphologic, immunologic and cytogenetic parameters, allowed us to carefully identify the transition from one chronic myeloproliferative disease (MPD) to another. This is only the second case reported showing a clinical evolution of this nature. The clinical and biological aspects of the disease are briefly discussed.
Leukemia & Lymphoma | 1993
Sergio Ferrari; Alexis Grande; Patrizia Zucchini; Rossella Manfredini; Enrico Tagliafico; Elena Rossi; Paola Temperani; Giuseppe Torelli; Giovanni Emilia; Umberto Torelli
The expression of c-kit and its ligand, the stem cell factor (SCF), was studied in five cases of acute myeloid leukemia. One of these had a trisomy of chromosome 4, where the c-kit oncogene is located. In this case, the c-kit oncogene was overexpressed, but matched by a low expression of its ligand, SCF. The molecular evaluation of the growth rate by c-myc and the histone H3 expression indicated that the growth fraction of this cell population was very low. In one of the other leukemic cell populations studied, characterized by a low expression of c-kit and an elevated expression of the SCF, the growth fraction was also very low. Our results suggest that at least for some receptor oncogenes, the simple overexpression cannot be taken as an indication that the oncogene is involved in the deregulation of cell proliferation.
Leukemia | 2007
Rossana Maffei; Roberto Marasca; Silvia Martinelli; Ilaria Castelli; Elena Morandi; Patrizia Zucchini; Marcella Fontana; Francesca Giacobbi; Paola Silingardi; Goretta Bonacorsi; Paola Temperani; Laura Masini; Am Colacci; Roberto Serra; Giuseppe Torelli
Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status
Leukemia | 2002
Barbara Crescenzi; Stefano Sacchi; Roberto Marasca; Paola Temperani; R La Starza; Caterina Matteucci; Goretta Bonacorsi; Silvia Romoli; M F Martelli; C. Mecucci; Giovanni Emilia
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia
Cancer Genetics and Cytogenetics | 1989
Giovanni Emilia; Paola Temperani; Sergio Ferrari; Patrizia Zucchini; Enrico Tagliafico; Licia Selleri; Giuseppe Torelli; Tullio Artusi; Umberto Torelli
Cytogenetic and molecular data of three patients affected by primary myelofibrosis with myeloid metaplasia (PMMM) evolving to blastic crisis are reported. The cytogenetic findings were uncommon. The first patient (female) showed an idic(X)(q13) as the sole alteration in chronic phase, with an additional r(7) in 67% of the cells of the blast crisis; the other two patients showed, in blast crisis, a partial trisomy of the long arm of chromosome 1, without translocation, as a unique structural abnormality. These findings confirm the presence of nonrandom, although nonspecific, alterations in PMMM that, in our cases, seem to be related to the multistep progression of the neoplastic process. Molecular investigations have been applied to study the genomic organization and the level of expression of genes such as bcr and calcyclin and c-fms protooncogene possibly involved in the molecular mechanisms underlying cell proliferation in hematopoietic cells. The data obtained are discussed with respect to the myeloproliferative disorder.
Cancer Genetics and Cytogenetics | 1998
Giovanni Emilia; Mario Luppi; Mg Ferrari; Paola Temperani; Roberto Marasca; Francesca Giacobbi; P. Vaccari; Elena Bandieri; C. Di Donato; C. Carapezzi; Giuseppe Torelli
Ph-positive chronic myeloid leukemia (CML) mimicking essential thrombocythemia (ET) at onset seems to be a distinct clinical entity. Whether this rare clinical form of CML is associated with single, specific variants of BCR/ABL transcripts is a matter of debate. Among 82 consecutive patients with Ph-positive CML, we identified 3 patients in which the disease mimicked ET at presentation, because of marked thrombocytosis and moderate leukocytosis, with few immature myeloid cells in peripheral blood and blood basophilia in 2 of them. Molecular analysis with the reverse transcriptase-polymerase chain reaction technique showed the presence of b2a2, b3a2, and b3a2-b2a2 transcript variants in the three patients, respectively. The results of our study together with a review of literature data suggest that different BCR/ABL transcript variants may occur in CML mimicking ET, without an apparently significant prevalence of one type.
Cancer Genetics and Cytogenetics | 1995
Giovanni Emilia; Roberto Marasca; Giuseppe Longo; Maria Grazia Ferrari; Mathilda Notohamiprodjo; Paola Temperani; Stefano Sacchi; Giuseppe Torelli
A 39-year-old woman was diagnosed with acute promyelocytic leukemia (APL) with disseminated intravascular coagulation syndrome. The hematologic examination showed a morphologic, cytochemical, and immunophenotypic picture typical of an APL, with a marked leukocytosis and a mixed population of hypergranular and microgranular promyelocytes. The cytogenetic analysis showed a 46,XX,t(9;22) karyotype, without any alterations of chromosomes 15 and 17. The t(15;17) translocation was not evident in FISH experiments, while a molecular analysis revealed the presence of a PML-RAR alpha chimera.